Here we have further developed this tumor-specific neovascular targeting approach by using bi-specific NGR peptides that recognize both CD13 and αvβ3 integrin, in order to lower the dose escalation and achieve more physiologic targeting of tumor neovasculature to avoid potential negative side effects. The gene discussed is ANPEP; the disease is neoplasm.